Agenda
- Overview of CAR T-Cell Therapy
- What Makes a Patient a Candidate for CAR T-Cell Therapy?
- The Referring Oncologist Experience: Coordination of Care
- Effectively Identifying, Managing, and Referring Unique CAR T-Cell–Mediated Adverse Events
Events
Date / Time
Event Details
Faculty
Faculty
Jesús G. Berdeja, MD
Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee
Faculty
Caron Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Faculty
Loretta Nastoupil, MD
Associate Professor
Department of Lymphoma/Myeloma
University of Texas MD Anderson Cancer Center
Houston, Texas
Faculty
Joshua Sasine, MD, PhD
Assistant Professor of Medicine
Co-Director, CAR T Program
Division of Hematology and Cellular Therapy
Cedars-Sinai Medical Center
Los Angeles, California
Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of clinicians practicing in community settings managing patients eligible for, or who have received CAR T-Cell therapy.
Target Audience
This program is intended for hematologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with hematologic malignancies who may benefit from or who have received CAR T-cell therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall the scientific principles underlying the use of CAR T-cells
- Identify patients who are likely to benefit from CAR T-cell therapy and refer to the appropriate authorized center for treatment or clinical trial enrollment
- Determine best practices for timely referral of appropriate patients for CAR T-cell therapy and develop proper channels of communication between community and academic centers to streamline the logistics of delivering therapy
- Apply multidisciplinary interventions to monitor, identify, and manage acute toxicities and ensure patient safety while receiving CAR T-cell therapy
- Integrate recent developments, clinical trial findings, and indications of recently approved and emerging CAR T-cell therapies into clinical practice to enhance clinical outcomes
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-126-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.